Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026)

Indivior Pharmaceuticals has reported Cash & Equivalents for 6 years, with the latest figure at $222.0 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 56.47% year-over-year to $222.0 million in Q2 2026; TTM through Jun 2026 was $222.0 million, a 56.47% decrease from a year earlier, with the FY2025 full-year figure at $195.0 million, down 38.87% from the prior year.
• Cash & Equivalents was $222.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $175.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $774.0 million in Q4 2022, with the low at $175.0 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $369.8 million, with a median of $319.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 59.17% in 2023, then rose 0.95% in 2024.
• Over 5 years, Cash & Equivalents stood at $774.0 million in 2022, then tumbled by 59.17% to $316.0 million in 2023, then advanced by 0.95% to $319.0 million in 2024, then sank by 38.87% to $195.0 million in 2025, then rose by 13.85% to $222.0 million in 2026.
• The last three Cash & Equivalents figures came in at $222.0 million (Q2 2026), $175.0 million (Q1 2026), and $195.0 million (Q4 2025), per Business Quant data.